Last reviewed · How we verify
Co-Analgesic Therapy
Co-Analgesic Therapy is a Small molecule drug developed by VA Office of Research and Development. It is currently in Phase 1 development.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Co-Analgesic Therapy |
|---|---|
| Sponsor | VA Office of Research and Development |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- The Analgesic Efficacy and Safety of Mirogabalin in Patients With Herpes Zoster (NA)
- The Effect of Chiropractic Care on Opioid Use for Chronic Spinal Pain: A Feasibility Study (NA)
- Safety of Nerivio in Pregnant Women With Migraine
- Evaluation Of The Influence Of Anesthetic Interventions On The Evolution Of Hepatic Neoplastic Processes (NA)
- Pain Control With Caudal Epidural vs. Combined Caudal Epidural and Lumbar Sympathetic Block . (NA)
- Morphine After Radiofrequency Ablation of Painful Bone Metastases in Patients With Cancer (PHASE2)
- Percutaneous Radiofrequency Ablation of Parietal Endometriosis (PRFA) (NA)
- Peripheral KV7 Activation for Pain Relief (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Co-Analgesic Therapy CI brief — competitive landscape report
- Co-Analgesic Therapy updates RSS · CI watch RSS
- VA Office of Research and Development portfolio CI
Frequently asked questions about Co-Analgesic Therapy
What is Co-Analgesic Therapy?
Who makes Co-Analgesic Therapy?
What development phase is Co-Analgesic Therapy in?
Related
- Manufacturer: VA Office of Research and Development — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing